Samsung Biologics, a leading global contract development and manufacturing organization, achieved record-breaking earnings in the first half of this year, surpassing 2 trillion won ($1.5 billion). The company reported consolidated revenue of 2.1 trillion won and an operating profit of 655.8 billion won for the first half, marking year-on-year increases of 33 percent and 47 percent, respectively. These impressive results were attributed to the full utilization of its three plants and the ramp-up of its newest Plant 4 operations. Furthermore, Samsung Biologics secured contracts with 16 of the top 20 global pharmaceutical companies, with a cumulative contract volume exceeding $13 billion as of June. Samsung Biologics' CEO, John Rim, highlighted the company's commitment to client satisfaction and high-quality biomedicines, emphasizing the steady business growth driven by robust partnerships with global pharma and biotech companies. The company also made strategic investments in diverse modalities, including a recent investment in Latus Bio, a US-based biotech company specializing in novel gene therapy for central nervous system disorders. Looking ahead, the company plans to complete the construction of its standalone antibody-drug conjugate facility by the end of this year and aims to have Plant 5 operational by April 2025. Additionally, Samsung Biologics continues to launch innovative platforms to accelerate biopharmaceutical development and offers customized solutions through SelecTailor to meet the specific needs of its clients. This news release showcases Samsung Biologics' remarkable financial performance, its strong partnerships with global pharmaceutical companies, and its strategic investments in expanding its capabilities and capacity.